THE TREATMENT OF NEOVASCULAR GLAUCOMA CAUSED BY CENTRAL VEIN OCCLUSION WITH CYCLOCRYOTHERAPY-A CASE REPORT
A case report
Glaucoma is the world's number one cause of irreversible blindness. Worldwide, there are over 65 million people diagnosed with various types of glaucoma. According to the latest definitions, it is a neuropathic progressive disease of the optic nerve. The main divisions are primary open and closed angle glaucoma and secondary glaucoma which is caused by various systemic or local diseases. Among the most common types of secondary glaucoma is neovascular glaucoma, which can be caused by diabetic retinopathy, arterial hypertension, various vasculopathies, inflammatory processes of the eye, trauma and other factors. Neovascular glaucoma is a serious and aggressive form of glaucoma that has rapid progression and manifestations. The main symptoms are high eye pressure, pain, redness and the appearance of small vessels in the iris.There are various treatments for this disease, but mainly they are aimed at relieving the symptoms or reducing the progression of the disease. The most important therapeutic options, apart from anti-glaucoma drugs, are the application of anti-Vegf therapy and cyclodestructive treatments, which enable the reduction of intraocular pressure and alleviation of symptoms, thus enabling patients to have a better quality of life.The aim of our study was to prove the impact of cyclocryotherapy in reducing intraocular pressure in a 43-year-old female patient. age with neovascular glaucoma of the left eye. The pressure before the intervention was 41.4 mmHg, while after the intervention it decreased to 26.6 mmHg, also the symptoms such as pain and redness subsided.
Key words; Neovascular glaucoma, retinal vein occlusion, cyclo-cryotherapy.
2. Sparrow JR. Comment and response to the article “The clinical relevance of visualizing the peripheral retina” by Nicola Quinn, Lajos Csincsik, Erin Flynn, Christine A. Curcio, Szilard Kiss, SriniVas R. Sadda, Ruth Hogg, Tunde Peto & Imre Lengyel. Prog Retin Eye Res. 2021;83:1000939.
3. Olmos LC, Sayed MS, Moraczewski AL, Gedde SJ, Rosenfeld PJ, Shi W, Feuer WJ, Lee RK. Long-term outcomes of neovascular glaucoma treated with and without intravitreal bevacizumab. Eye (Lond) 2016;30(3):463–472.
4. Widder R, Lemmen KD, Dietlein T. Neovaskularisationsglaukom. Klin Monatsbl Augenheilkd. 2010;227(2):R15–R28.
5. Zhou MW, Xu X, Zhang XL, Sun XD. Clinical outcomes of Ahmed glaucoma valve implantation with or without intravitreal bevacizumab pretreatment for neovascular glaucoma: a systematic review and meta-analysis. J Glaucoma. 2016;25(7):551–557.
6. Lang, Ophthalmology 2000,Gerhard K.LANG M.D p.336-339
7. Al Faran MF, Tomey KF, Al Mutlag FA. Cyclocryotherapy in selected cases of congenital glaucoma. Ophth Surg. 1990;21:794-798.
8. Wagle NS, Freedman SF, Buckley EG, Davis JS, Biglan AW. Long-term outcome of cyclocryotherapy for refractory pediatric glaucoma. 1998;105(10):1921-1926; discussion 1926-1927.
9. Bellows AR. Cyclocryotherapy: Its role in the treatment of glaucoma. Perspect Ophthalmol. 1980;4:139.
10. Treatment of Neovascular Glaucoma with Transscleral Panretinal Cryotherapy
Donald R. May MD et al. Ophthalmology Volume 87, Issue 11, November 1980, Pages 1106-1111
11. Bietti G. Surgical intervention on the ciliary body; new trends for the relief of glaucoma. J Am Med Assoc. 1950;142:889–97.
12. Benson MT, Nelson ME. Cyclocryotherapy: a review of cases over a 10-year period. Br J Ophthalmol. 1990;74:103–5.
13. https://www.aao.org/image.axd?id=662d2f86-0fa1-41b9-a493 8a9 ffaf8d749&t= 6358259969 204 30 000